NCT02812771CompletedPhase 4
A Multicenter, Open Label, Single-arm Study Evaluating the Safety and Pharmacokinetics of Efinaconazole Topical Solution in Subjects With Mild to Severe Onychomycosis of the Toenails
Bausch Health Americas, Inc.10 sites in 2 countries62 target enrollmentStarted: August 4, 2016Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 4
- Status
- Completed
- Sponsor
- Bausch Health Americas, Inc.
- Enrollment
- 62
- Locations
- 10
- Primary Endpoint
- Percentage of Participants With at Least One Adverse Event
Study Overview
Brief Summary
Safety and Pharmacokinetics (PK) of a once daily topical application of efinaconazole in the treatment of pediatric subjects with mild to severe onychomycosis of the toenails.
Detailed Description
This is an open label, single-arm study designed to evaluate the safety and PK of a once daily topical application of efinaconazole in the treatment of pediatric subjects with mild to severe onychomycosis of the toenails.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 6 Years to 16 Years (Child)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Male or female subjects of any race, 6 to 16 years of age (inclusive). PK Subset: Male or female subjects of any race, 12 to 16 years of age (inclusive).
- •Verbal and written informed consent/assent obtained from the subject and/or their parent or legal guardian.
- •Good general health, as assessed by the investigator, based on the subject's medical history, physical examination, and safety laboratory tests.
- •Target great toenail for all subjects, and both great toenails for subjects in the PK subset, must have evidence of toenail growth, per subject's report that monthly clipping is needed.
- •Subjects and their parents/legal guardians are willing to comply with study instructions and return to the investigational center for all required visits (a visit schedule with the length of each visit will be provided to ensure that the subject can meet the requirements and have adequate transportation).
Exclusion Criteria
- •Females who are pregnant, nursing an infant, or planning a pregnancy during the study period.
- •History of immunosuppression and/or clinical signs indicative of possible immunosuppression, as determined by the investigator, or known human immunodeficiency virus infection.
- •History of diabetes that is uncontrolled as determined by the investigator (diabetes that is controlled by diet or medication does not exclude a subject).
- •Presence of any toenail infection other than or in addition to dermatophytes, such as Scytalidium as determined by the investigator (candidal onychomycosis infection, concurrent with a positive dermatophyte culture, is acceptable).
Arms & Interventions
Efinaconazole
Experimental
Efinaconazole
Intervention: Efinaconazole (Drug)
Outcomes
Primary Outcomes
Percentage of Participants With at Least One Adverse Event
Time Frame: 48 weeks
Secondary Outcomes
No secondary outcomes reported
Investigators
Study Sites (10)
Loading locations...
Similar Trials
Completed
Phase 1
An Study to Evaluate the Effects of Fluconazole on the Pharmacokinetics (PK) of Sativex® in Healthy Subjects With Cannabis Experience.Healthy SubjectsNCT02325011Jazz Pharmaceuticals14
Completed
Phase 1
A Study to Determine the Effects of Itraconazole on the Pharmacokinetics (PK) of DS-8500 in Healthy SubjectsPharmacokineticsNCT02790671Daiichi Sankyo26
Completed
Phase 1
A Study to Assess LY4100511 (DC-853) in Healthy Adult ParticipantsHealthyNCT06345794DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company50
Completed
Phase 1
To Evaluate the Effect of Multiple Doses of Itraconazole on the Pharmacokinetics of BV100Bacterial InfectionsNCT05684718BioVersys AG16
Completed
Phase 1
Effect of Fluconazole on the Pharmacokinetics of Pyrotinib in Healthy SubjectsHealthy SubjectsNCT04850651Jiangsu HengRui Medicine Co., Ltd.18